Dogecoin's price fell 8.6% over seven days to $0.0791 despite large holders buying 600 million DOGE worth about $47.5 million between October 12-16. The price drop is attributed to a sharp 49% decline in daily turnover to $590 million, thinning the order book and amplifying price moves. New daily supply of 13.82 million DOGE adds selling pressure, making recent buying insufficient to boost prices. Investors should consider order book depth and use limit orders to avoid higher costs in this thin market. The buying signals demand but turnover must recover for a sustained price rise.
Dogecoin market activity provides context for readers. Among 50 major cryptocurrencies on Pluang, 23 rose and 25 fell as of Oct 19, 2026, 19:21 WIB. Notable movers include Fantom (FTM) at Rp11.382, down 2.05% with a typical hold time of 88 days, PancakeSwap (CAKE) at Rp38.748, down 2.02% with 87% sell order activity, and Enjin Coin (ENJ) at Rp486, down 1.94% with 95% sell order activity.
Nyxoah announced preliminary Q3 2026 revenue of €9.2 million, up 19% sequentially, driven by a 29% increase in U.S. sales. The company submitted a PMA supplement to the FDA to expand its Genio device indication for patients with complete concentric c...
ASML Holding N.V. announced recent transactions under its ongoing share buyback program, repurchasing a total of 233,867 shares between October 12 and October 16, 2026. The shares were bought back at weighted average prices ranging from €1,444.83 to ...
The Phase 3 ALKIVIA trial demonstrated that efgartigimod significantly improves symptoms in patients with autoimmune myositis, including immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM). Patients showed meaningful clinical improve...
In 2025, Berkshire Hathaway, led by Greg Abel, received $479 million in dividends from its $1.3 billion investment in American Express. This highlights the value of holding strong dividend-paying stocks for steady income. Retail investors can apply s...
Lexeo Therapeutics announced an educational event on October 21, 2026, focusing on clinical endpoints and outcome measures in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). The event will feature discussions by Lexeo's Chief Medical Officer and a lea...
